Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...
JanOne, formerly Appliance Recycling Centers of...
Microbotâ˘, which was founded in 2010 and commenced operations in 2011, became a ...
Microbotâ˘, which was founded in 2010 and comm...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical com...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a c...
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
Join the National Investor Network and get the latest information with your interests in mind.